A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Sickle Cell Disease
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
-
Mount Sinai Hospital, New York, New York, United States, 10029
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Icahn School of Medicine at Mount Sinai,
Susanna Curtis, PRINCIPAL_INVESTIGATOR, MOUNT SINAI HOSPITAL
2026-06-01